112 results
6-K
EX-99.1
GLPG
Galapagos NV
30 May 24
Current report (foreign)
4:44pm
, the potential benefits of Adaptimmune’s TCR-T therapy, uza-cel, and the potential benefits of Galapagos’ decentralized T-cell manufacturing platform … , including the potential benefits of such collaboration may be incorrect, the inherent uncertainties associated with competitive developments
6-K
EX-99.1
GLPG
Galapagos NV
16 May 24
Current report (foreign)
8:11am
with Blood Centers of America, including the benefits of such collaboration, and statements regarding Galapagos’ CAR-T manufacturing platform. Forward … the potential benefits of such collaboration, may be incorrect, the inherent uncertainties associated with competitive developments and regulatory
6-K
EX-99.1
GLPG
Galapagos NV
3 May 24
Galapagos reports first quarter 2024 financial results
9:30am
related to the acquisitions of CellPoint and AboundBio, including the risk that we may not achieve the anticipated benefits of the acquisitions of CellPoint … the anticipated benefits of such exercise on the currently envisaged timeline or at all. A further list and description of these risks, uncertainties and other
6-K
GLPG
Galapagos NV
1 May 24
Current report (foreign)
5:10pm
: Each new share to be issued by the Company upon each exercise of the Warrant shall be fully paid up and shall have the same rights and benefits
6-K
EX-99.3
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
by the Company upon each exercise of the Warrant shall be fully paid up and shall have the same rights and benefits as, and rank pari passu in all respects
6-K
EX-99.5
afob80nry6gjq f5f
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.14
txlbr l99z1tozjyzs
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.2
axixtvu0fj3qly69qeyi
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.15
3hsgj
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.7
xz172pv7j3i27
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.4
dho5wwwz8xgh577cal7
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.1
kkrpc rbdewdsmuyxjl1
29 Mar 24
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
6:14am
6-K
EX-99.1
u6g9npi4mpwwqim
23 Feb 24
Galapagos announces full year 2023 results and outlook for 2024
6:41am
6-K
EX-99.1
5ewxiq9vvbftpc
4 Jan 24
Current report (foreign)
5:32pm
6-K
EX-99.1
0wf8vg ok
4 Jan 24
Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology
4:07pm